Dr Reddy′s launches anti-coagulant drug in US market

Hyderabad-based drug major Dr Reddy′s Laboratories announced the launch of anti-coagulant drug Aspirin and extended-release dipyridamole capsules in the US market. The product is a therapeutic equivalent to a generic version of Aggrenox (aspirin and extended-release dipyridamole) capsules, the company said in a BSE filing. Quoting IMS Health data, Dr Reddy′s Laboratories said the Aggrenox brand and generic had US sales of approximately $182 million for the most recent 12 months ending in October 2018. Dr Reddy′s Aspirin and extended-release Dipyridamole capsules are available in 25 mg/200 mg strength with 60 count bottle size. Aggrenox is a trademark of Boehringer lngelheim.